Association of polymorphisms of rs179247 and rs12101255 in thyroid stimulating hormone receptor intron 1 with an increased risk of Graves’ disease: A meta-analysis

  • Jing Gong (巩 静)
  • Shu-jun Jiang (姜淑君)
  • Ding-kun Wang (王定坤)
  • Hui Dong (董 慧)
  • Guang Chen (陈 广)
  • Ke Fang (方 珂)
  • Jin-rui Cui (崔金锐)
  • Fu-er Lu (陆付耳)Email author


The polymorphisms of thyroid stimulating hormone receptor (TSHR) intron 1 rs179247 and rs12101255 have been found to be associated with Graves’ disease (GD) in genetic studies. In the present study, we conducted a meta-analysis to examine this association. Two reviewers systematically searched eligible studies in PubMed, Web of Science, Embase and China Biomedical Literature Database (CBM). A meta-analysis on the association between GD and TSHR intron 1 rs179247 or rs12101255 was performed. The odd ratios (OR) were estimated with 95% confidence interval (CI). Meta package in R was used for the analyses. Seven articles (13 studies) published between 2009 and 2014, involving 5754 GD patients and 5768 controls, were analyzed. The polymorphism of rs179247 was found to be associated with an increased GD risk in the allele analysis (A vs. G: OR=1.40, 95% CI=1.33–1.48) and all genetic models (AA vs. GG: OR=1.94, 95% CI=1.73–2.19; AA+AG vs. GG: OR=1.57, 95% CI=1.41–1.74; AA vs. AG+GG: OR=1.54, 95% CI=1.43–1.66). The site rs12101255 also conferred a risk of GD in the allele analysis (T vs. C: OR=1.50, 95% CI=1.40–1.60) and all genetic models (TT vs. CC: OR=2.22, 95% CI=1.92–2.57; TT+TC vs. CC: OR=1.66, 95% CI=1.50–1.83; TT vs. TC+CC: OR=1.74, 95% CI=1.53–1.98). Analysis of the relationship between rs179247 and Graves’ ophthalmopathy (GO) showed no statistically significant correlation (A vs. G: OR=1.02, 95% CI=0.97–1.07). Publication bias was not significant. In conclusion, GD is associated with polymorphisms of TSHR intron 1 rs179247 and rs12101255. There is no association between rs179247 SNPs and GO.


Graves’ disease Graves’ ophthalmopathy genetic polymorphism meta-analysis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Weetman AP. Graves’ disease. N Engl J Med, 2000,343(17):1236–1248CrossRefPubMedGoogle Scholar
  2. 2.
    Bartalena L. Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol, 2013,9(12): 724–734CrossRefPubMedGoogle Scholar
  3. 3.
    Teng W, Shan Z, Teng X, et al. Effect of iodine intake on thyroid diseases in China. N Engl J Med, 2006,354(26):2783–2793CrossRefPubMedGoogle Scholar
  4. 4.
    McLeod DS, Cooper DS. The incidence and prevalence of thyroid autoimmunity. Endocrine, 2012,42(2):252–265CrossRefPubMedGoogle Scholar
  5. 5.
    Effraimidis G, Wiersinga WM. Mechanisms in endocrinology: autoimmune thyroid disease: old and new players. Eur J Endocrinol, 2014,170(6):R241–R252CrossRefPubMedGoogle Scholar
  6. 6.
    Brix TH, Christensen K, Holm NV, et al. A population-based study of Graves’ disease in Danish twins. Clin Endocrinol, 1998,48(4):397–400CrossRefGoogle Scholar
  7. 7.
    Roelfsema F, Veldhuis JD. Thyrotropin secretion patterns in health and disease. Endocr Rev, 2013,34(5):619–657CrossRefPubMedGoogle Scholar
  8. 8.
    Smith BR, Sanders J, Furmaniak J. TSH receptor antibodies. Thyroid, 2007,17(10):923–938CrossRefPubMedGoogle Scholar
  9. 9.
    McLachlan SM, Rapoport B. Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity. Endocr Rev, 2014,35(1):59–105CrossRefPubMedGoogle Scholar
  10. 10.
    Muhlberg T, Herrmann K, Joba W, et al. Lack of association of nonautoimmune hyperfunctioning thyroid disorders and a germline polymorphism of codon 727 of the human thyrotropin receptor in a European Caucasian population. J Clin Endocrinol Metab, 2000,85(8):2640–2643PubMedGoogle Scholar
  11. 11.
    Ban Y, Greenberg DA, Concepcion ES, et al. A germline single nucleotide polymorphism at the intracellular domain of the human thyrotropin receptor does not have a major effect on the development of Graves’ disease. Thyroid, 2002,12(12):1079–1083CrossRefPubMedGoogle Scholar
  12. 12.
    Zeitlin AA, Simmonds MJ, Gough SC. Genetic developments in autoimmune thyroid disease: an evolutionary process. Clin Endocrinol, 2008,68(5):671–682CrossRefGoogle Scholar
  13. 13.
    Chistiakov DA, Savost’anov KV, Turakulov RI, et al. Further studies of genetic susceptibility to Graves’ disease in a Russian population. Med Sci Monit, 2002, 8(3):CR180–CR184PubMedGoogle Scholar
  14. 14.
    Ho SC, Goh SS, Khoo DH, et al. Association of Graves’ disease with intragenic polymorphism of the thyrotropin receptor gene in a cohort of Singapore patients of multi-ethnic origins. Thyroid, 2003,13(6):523–528CrossRefPubMedGoogle Scholar
  15. 15.
    Dechairo BM, Zabaneh D, Collins J, et al. Association of the TSHR gene with Graves’ disease: the first disease specific locus. Eur J Hum Genet, 2005,13(11):1223–1230CrossRefPubMedGoogle Scholar
  16. 16.
    Hiratani H, Bowden DW, Ikegami S, et al. Multiple SNPs in intron 17 of thyrotropin receptor are associated with Graves disease. J Clin Endocrinol Metab, 2005,90(5): 2898–2903CrossRefPubMedGoogle Scholar
  17. 17.
    Brand OJ, Barrett JC, Simmonds MJ, et al. Association of the thyroid stimulating hormone receptor gene (TSHR) with Graves’ disease. Hum Mol Genet, 2009,18(9):1704–1713CrossRefPubMedGoogle Scholar
  18. 18.
    Liu L, Wu HQ, Wang Q, et al. Association between thyroid stimulating hormone receptor gene intron polymorphisms and autoimmune thyroid disease in a Chinese Han population. Endocr J, 2012,59(8):717–723CrossRefPubMedGoogle Scholar
  19. 19.
    Ploski R, Brand OJ, Jurecka-Lubieniecka B, et al. Thyroid stimulating hormone receptor (TSHR) intron 1 variants are major risk factors for Graves’ disease in three European Caucasian cohorts. PloS one, 2010,5(11):e15512CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Inoue N, Watanabe M, Katsumata Y, et al. Different genotypes of a functional polymorphism of the TSHR gene are associated with the development and severity of Graves’ and Hashimoto’s diseases. Tissue Antigens, 2013,82(4):288–290PubMedGoogle Scholar
  21. 21.
    Wang HL, Yang L, Jia Z, et al. Correlation of gene polymorphism and Graves’ disease in Han nationality in the coastal region of Shandong Province. Chin J Endocrinol Metabol (Chinese), 2013,29(2):108–111Google Scholar
  22. 22.
    Wang R, Zhang X, Liu BL, et al. Association of polymorphisms of TSHR gene intron 1 with Graves disease. Chin J Endocrinol Metabol (Chinese), 2012,28(4):306–310Google Scholar
  23. 23.
    Yang SY, Liu W, Xue LQ, et al. Relation between poly-morphisms in TSHR gene intron 1 and Graves’s disease. Chin J Endocrinol Metabol (Chinese), 2011,27(6): 478–481Google Scholar
  24. 24.
    Liu BL, Yang SY, Liu W, et al. Refined association of TSH receptor susceptibility locus to Graves’ disease in the Chinese Han population. Eur J Endocrinol, 2014,170(1): 109–119CrossRefPubMedGoogle Scholar
  25. 25.
    Colobran R, Armengol Mdel P, Faner R, et al. Association of an SNP with intrathymic transcription of TSHR and Graves’ disease: a role for defective thymic tolerance. Hum Mol Genet, 2011,20(17):3415–3423CrossRefPubMedGoogle Scholar
  26. 26.
    Xu LD, Zhang XL, Sun HM, et al. Lack of association between thyroid-stimulating hormone receptor haplotypes and Graves’ disease in a northern Chinese population. Tissue Antigens, 2011,77(1):2CrossRefPubMedGoogle Scholar
  27. 27.
    Menconi F, Marcocci C, Marino M. Diagnosis and classification of Graves’ disease. Autoimmun Rev, 2014,13(4-5):398–402CrossRefPubMedGoogle Scholar
  28. 28.
    Eckstein AK, Johnson KT, Thanos M, et al. Current insights into the pathogenesis of Graves’ orbitopathy. Horm Metab Res, 2009,41(6):456–464CrossRefPubMedGoogle Scholar
  29. 29.
    Jurecka-Lubieniecka B, Ploski R, Kula D, et al. Association between polymorphisms in the TSHR gene and Graves’ orbitopathy. PloS One, 2014,9(7):e102653CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Xiong JQ, Li Y, Huang K, et al. Association between DAPK1 promoter methylation and cervical cancer: a meta-analysis. PloS One, 2014,9(9):e107272CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Chu X, Pan CM, Zhao SX, et al. A genome-wide association study identifies two new risk loci for Graves’ disease. Nat Genet, 2011,43(9):897–901CrossRefPubMedGoogle Scholar
  32. 32.
    Bufalo NE, Dos Santos RB, Marcello MA, et al. TSHR intronic polymorphisms (rs179247 and rs12885526) and their role in the susceptibility of the Brazilian population to Graves’ disease and Graves’ ophthalmopathy. J Endocrinol Invest, 2014, doi:10.1007Google Scholar
  33. 33.
    Chistiakov DA. Thyroid-stimulating hormone receptor and its role in Graves’ disease. Mol Genet Metab, 2003,80(4):377–388CrossRefPubMedGoogle Scholar
  34. 34.
    Gerding MN, Terwee CB, Dekker FW, et al. Quality of life in patients with Graves’ ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument. Thyroid, 1997,7(6):885–889CrossRefPubMedGoogle Scholar
  35. 35.
    Gianoukakis AG, Smith TJ. Recent insights into the pathogenesis and management of thyroid-associated ophthalmopathy. Curr Opin Endocrinol Diabetes Obes, 2008,15(5):446–452CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Li H, Chen Q. Genetic susceptibility to Grave’s disese. Front Biosci, 2013,18:1080–1087CrossRefGoogle Scholar
  37. 37.
    Bednarczuk T, Gopinath B, Ploski R, et al. Susceptibility genes in Graves’ ophthalmopathy: searching for a needle in a haystack? Clin Endocrinol, 2007,67(1):3–19CrossRefGoogle Scholar
  38. 38.
    Gu LQ, Zhu W, Zhao SX, et al. Clinical associations of the genetic variants of CTLA-4, Tg, TSHR, PTPN22, PTPN12 and FCRL3 in patients with Graves’ disease. Clin Endocrinol, 2010,72(2):248–255CrossRefGoogle Scholar
  39. 39.
    Yin X, Latif R, Bahn R, et al. Influence of the TSH receptor gene on susceptibility to Graves’ disease and Graves’ ophthalmopathy. Thyroid, 2008,18(11):1201–1206CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Huazhong University of Science and Technology and Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Jing Gong (巩 静)
    • 1
  • Shu-jun Jiang (姜淑君)
    • 1
  • Ding-kun Wang (王定坤)
    • 1
  • Hui Dong (董 慧)
    • 1
  • Guang Chen (陈 广)
    • 1
  • Ke Fang (方 珂)
    • 1
  • Jin-rui Cui (崔金锐)
    • 2
  • Fu-er Lu (陆付耳)
    • 1
    Email author
  1. 1.Institute of Integrated Traditional Chinese and Western MedicineHuazhong University of Science and TechnologyWuhanChina
  2. 2.Department of Nursing Care, Tongji Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina

Personalised recommendations